Kevin Kunzmann

The guidance clarification published today comes just a day after reports a polarizing guidance was published last month without full review nor consensus from the agency.

Officials state the controversial August guidance was influenced by other federal agencies, and that revisions may come soon.

A look into the long-term implications of the virus on athletes' cardiovascular fitness.

What we've seen non-immunized communities do for previously eradicated outbreaks.

New ACTT-2 findings show notable promise for a combination of the rheumatoid arthritis drug and the EUA-approved antiviral therapy.

A discussion with an Ohio State investigator on early CMR findings among young athletes.

Investigators resumed phase 3 international assessments after independent committees and regulators deemed it safe to do so.

New research presented at ERS shows how critically ill COVID-19 patients face cardiac and pulmonary burdens weeks after recovery.

How a Chicago-based surgeon managed an unprecedented procedure for young woman at the height of the pandemic.

A new report shows a UK-based participant experienced a serious adverse event, but is anticipated to recover.

The phase 1/2 findings show the recently regulated two-dose vaccine was associated with no serious adverse events and antibody response within 21 days.

At a time when schools and college campuses have reopened, an expert discusses adolescents' trends in spreading COVID-19 more easily, and the lack of testing available to them.

How children and adolescents contract, spread, and suffer through the virus differently than other age groups.

A team at UCSF has created a model which estimates how many pediatric cases are going unnoticed in any US county at any time.

The 15-minute test was granted emergency authorization by the FDA earlier this week.

The device has test result features likened to pregnancy tests, and can be produced vastly every month.

Brad Spellberg, MD, explains how real progress can be made to a debted system with worsened rates of user health.

Investigators report comparable SARS-CoV-2 neutralizing antibody counts across age groups, as well as favorable safety outcomes for the two-dose vaccine.

Brad Spellberg, MD, discusses how the subspecialty lost "ownership" of its opportunities for pattented prescribing and referral years ago.

Investigators observed a second set of virus in a previously infected 33-year-old man, nearly 5 months after his first positive COVID-19 case.

An infectious disease chief medical officer discusses the cracks in US healthcare exposed by the pandemic.

The newest authorization comes following a week of clinical, legislative, and public health debate surrounding the realistic benefit of the survivor-extracted therapy.

Pediatricians agree schools are critical for child development and mental health. But their safety from the pandemic cannot be comprised for it.

From immunity building to plasma research, a look at some lesser efficient practices adopted or proposed during the pandemic.

July ended with nearly 100,000 new cases among children in the US. What does that mean for public and school reopenings?

A look at the processes and clinical practices at place to assure candidate safety during the COVID-19 vaccine race.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

The modified adenovirus-strain candidate did not reach phase 3 assessment, and was criticized by the WHO for being rushed through assessment.

A breakdown of how COVID-19 infection was not managed well in hospitals and ICUs early on.

The clearance for the phase 2 preventive trial will seek the oral antiviral's benefit in elderly care facilities.